Cindy Y. Jiang, MD

Peer-Reviewed Articles

1. Thomas Z, Johns AC, Glover M, Crupi E, Nieto YL, Ward JF, Karam JA, Hofstetter WL, Desai M, Choi SL, Shah AY, Lin J, Moussa MJ, Jiang CY, Alhalabi O, Campbell MT. Divergent biology and outcomes of somatic transformations in germ cell tumors. Oncologist 31(8), 2026. e-Pub 2026. PMID: 42378441.
2. Yu K, Chen J, Chu YY, Nair S, Crupi E, Hasanov E, Mei Y, Han X, Liu Y, Liu Y, Pei G, Peng F, Liao J, Dai E, Chu T, Cho KS, Jiang J, Yan X, Dai Y, Wang J, Zhang B, Genovese G, Putluri N, Eberlin L, Yang L, Lin C, Kwong LN, Shamsutdinova D, Wani KM, Czerniak BA, Yu W, Zhao J, Guo CC, Hansel D, Pettaway C, Pisters L, Bree K, Navai N, Lee BH, Kamat AM, Sharma P, Corn P, Jiang CY, Shah AY, Alhalabi O, Msaouel P, Siefker-Radtke AO, Logothetis CJ, Campbell MT, Lazar AJ, Gao J, Wang L. A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture. Cancer Discov, 2026. e-Pub 2026. PMID: 42126225.
3. Thomas, Z, Glover, M, Johns, AC, Moussa, MJ, Crupi, E, Lin, JK, Ward, JF, Karam, JA, Hofstetter, WL, Choi, S, Nieto, Y, Desai, M, Shah, AY, Jiang, CY, Alhalabi, O, Campbell, M. Circulating tumor DNA (ctDNA) as a real-time biomarker in marker-negative germ cell tumors (GCT). Journal of Clinical Oncology 44:619, 2026. e-Pub 2026.
4. Jang A, Jindal T, Khaki AR, Jiang CY, Alhalabi O, Nguyen CB, Tsung I, Oh E, Epstein I, Bakaloudi DR, Jaime-Casas S, Nizam A, Glover M, Mabey H, Taylor A, Evans S, Shin D, Pywell C, Abuqayas B, Barata PC, Zakharia Y, Basu A, Kilari D, Bilen MA, Emamekhoo H, Milowsky M, Hoimes CJ, Davis N, Shah S, Gupta S, Tripathi A, Grivas P, Bellmunt J, Alva A, Campbell MT, Chen Z, Fu P, Koshkin VS, Brown JR. Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database. Clin Genitourin Cancer 24(2):102501, 2026. e-Pub 2026. PMID: 41644316.
5. Jiang, CY, Hwang, H, Epstein, IY, Bakaloudi, DR, Talukder, R, Taylor, AK, Nizam, A, Jindal, T, Glover, MJ, Khaki, AR, Barata, P, Nguyen, CB, Oh, E, Davis, NB, Mabey, H, Hoimes, C, Evans, S, Abuqayas, B, Lemke, EA, Tsung, I, Qiao, W, Kilari, D, Zakharia, Y, Bilen, MA, Milowsky, MI, Shah, SA, Gupta, S, Emamekhoo, H, Bellmunt, J, Alva, A, Grivas, PD, Msaouel, P, Koshkin, VS, Campbell, M, Alhalabi, O. Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer. Oncologist 30(11), 2025. e-Pub 2025. PMID: 41056445.
6. Jindal T, Jiang CY, Alhalabi O, Davidsohn M, Freeman D, Epstein IY, Bakaloudi DR, Talukder R, Nizam A, Nguyen CB, Oh E, Tsung I, Glover MJ, Khaki AR, Taylor AK, Jaime-Casas S, Jang A, Lemke E, Pywell C, Evans ST, Shin D, Bilen MA, Basu A, Kilari D, Tripathi A, Brown J, Emamekhoo H, Davis NB, Shah S, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS. Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study. Urol Oncol 44(1):65.e1-65.e11, 2025. e-Pub 2025. PMID: 41152111.
7. Jiang CY, Hwang H, Epstein IY, Bakaloudi DR, Talukder R, Taylor AK, Nizam A, Jindal T, Glover MJ, Khaki AR, Barata PC, Nguyen CB, Oh E, Davis NB, Mabey H, Hoimes CJ, Evans ST, Abuqayas B, Lemke E, Tsung I, Qiao W, Kilari D, Zakharia Y, Bilen MA, Milowsky MI, Shah SA, Gupta S, Emamekhoo H, Bellmunt J, Alva AS, Grivas P, Msaouel P, Koshkin VS, Campbell MT, Alhalabi O. Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study. The Oncologist 30(11), 2025. e-Pub 2025.
8. Nizam A, Nguyen CB, Li J, Zabor EC, Msaouel P, Jiang CY, Alhalabi O, Oh E, Davidsohn MP, Epstein IB, Bakaloudi DR, Talukder R, Jindal T, Taylor AK, Glover MJ, Khaki AR, Lemke E, Mabey H, Abuqayas B, Jang A, Brown JR, Evans ST, Pywell C, Basu A, Bilen MA, Barata PC, Zakharia Y, Milowsky MI, Kilari D, Hoimes CJ, Shah SA, Emamekhoo H, Davis NB, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS. Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study. Cancer Med 14(19):e71284, 2025. e-Pub 2025. PMID: 41031719.
9. Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, Bakaloudi D, Davidsohn M, Freeman D, Glover M, Khaki AR, Evans S, Lemke E, Bose R, Sim W, Pywell C, Basu A, Kilari D, Barata PC, Bilen MA, Zakharia Y, Milowsky MI, Shah SA, Bellmunt J, Grivas P, Emamekhoo H, Davis NB, Gupta S, Hoimes C, Campbell MT, Alva A, Koshkin VS. Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data. Eur Urol Oncol 8(2):258-262, 2025. e-Pub 2025. PMID: 39709257.
10. Jiang CY, Zhao L, Green MD, Ravishankar S, Towlerton AMH, Scott AJ, Raghavan M, Cusick MF, Warren EH, Ramnath N. Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer. Sci Rep 14(1):345, 2024. e-Pub 2024. PMID: 38172168.
11. Jiang, CY, Hwang, H, Jindal, T, Qiao, W, Epstein, IB, Nguyen, CB, Gupta, S, Shah, SA, Bilen, MA, Milowsky, MI, Hoimes, C, Kilari, D, Zakharia, Y, Emamekhoo, H, Grivas, PD, Bellmunt, J, Alva, A, Koshkin, VS, Campbell, M, Alhalabi, O. Sequencing of erdafitinib (erda) and enfortumab vedotin (EV) in patients (pts) with fibroblast growth factor receptor (FGFR2/3) altered (alt) advanced urothelial cancer (aUC). Journal of Clinical Oncology 42(4), 2024. e-Pub 2024.
12. Jindal, T, Jiang, CY, Alhalabi, O, Nguyen, CB, Nizam, A, Basu, A, Bilen, MA, Zakharia, Y, Milowsky, MI, Brown, JR, Kilari, D, Emamekhoo, H, Hoimes, C, Khaki, AR, Gupta, S, Grivas, PD, Bellmunt, J, Campbell, M, Alva, A, Koshkin, VS. Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants. Journal of Clinical Oncology 42(4):652, 2024. e-Pub 2024.
13. Nizam, A, Jindal, T, Jiang, CY, Alhalabi, O, Davidsohn, M, Bakaloudi, DR, Talukder, R, Nguyen, CB, Oh, E, Taylor, AK, Bilen, MA, Basu, A, Kilari, D, Emamekhoo, H, Gupta, S, Grivas, PD, Bellmunt, J, Campbell, M, Alva, A, Koshkin, VS. Outcomes with sacituzumab govitecan (SG) in patients (pts) with advanced urothelial carcinoma (aUC) and variant histologies (VH). Journal of Clinical Oncology 42(4_suppl):667, 2024. e-Pub 2024.
14. Jiang CY, Zhao L, Schuetze SM, Chugh R. Giant Cell Tumor of Bone: Effect of Longer Dosing Intervals of Denosumab on Tumor Control and Bone-related Complications. Oncologist 27(7):595-599, 2022. e-Pub 2022. PMID: 35589095.
15. Jiang CY, Strohbehn GW, Dedinsky RM, Raupp SM, Pannecouk BM, Yentz SE, Ramnath N. Teleoncology for Veterans: High Patient Satisfaction Coupled With Positive Financial and Environmental Impacts. JCO Oncol Pract 17(9):e1362-e1374, 2021. e-Pub 2021. PMID: 34406817.
16. Jiang CY, Niu Z, Green MD, Zhao L, Raupp S, Pannecouk B, Brenner DE, Nagrath S, Ramnath N. It's not 'just a tube of blood': principles of protocol development, sample collection, staffing and budget considerations for blood-based biomarkers in immunotherapy studies. J Immunother Cancer 9(7), 2021. e-Pub 2021. PMID: 34321277.
17. Jiang CY, El-Kouri NT, Elliot D, Shields J, Caram MEV, Frankel TL, Ramnath N, Passero VA. Telehealth for Cancer Care in Veterans: Opportunities and Challenges Revealed by COVID. JCO Oncol Pract 17(1):22-29, 2021. e-Pub 2021. PMID: 32970512.
18. Mathur KM, Jiang C, Westerhoff M, Turgeon DK. More Than Just a Flare: Unexpected Findings of Disseminated Histoplasmosis in the Setting of TNF-α Blockade in a Patient with Ulcerative Colitis. Ann Gastroenterol Dig Dis.

Review Articles

1. Nizam, A, Jindal, T, Jiang, CY, Alhalabi, O, Bakaloudi, DR, Talukder, R, Davidsohn, M, Nguyen, CB, Oh, E, Taylor, AK, Lemke, EA, Kilari, D, Hoimes, C, Emamekhoo, H, Gupta, S, Bellmunt, J, Grivas, PD, Campbell, M, Alva, A, Koshkin, VS. Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study. Journal of Clinical Oncology 42:537, 2024. e-Pub 2024.

Abstracts

1. Jindal T, Jiang CY, Alhalabi O, Oh E, Jang A, Bellmunt J, Emamekhoo H, Hoimes CJ, Bilen MA, Zakharia Y, Gupta S, Milowsky M, Shah S, Basu A, Tripathi A, Grivas P, Brown J, Tsung I, Campbell MT, Koshkin VS. 3077P Enfortumab vedotin with pembrolizumab (EVP) treatment outcomes in patients with histologic subtypes of advanced urothelial carcinoma: analysis of the UNITE study. ESMO 2026, 2027.
2. Patel RR, Jiang CY, Thomas Z, Jindal T, Jang A, Zhong JY, Bakaloudi D, Oh E, Nguyen CB, Casas SJ, Tripathi A, Grivas P, Tsung I, Campbell MT, Alhalabi O, Khaki AR, Chen Z, Fu P, Koshkin VS, Robert Brown AJ. Risk and patterns of recurrence for patients (pts) with advanced urothelial carcinoma (aUC) metastatic to liver after response to enfortumab vedotin + pembrolizumab (EVP). ASCO 2026, 2026.
3. Jiang C, Navai N, Tidwell RS, Jindal S, Macaluso M, Siefker-Radtke AO, Goswami S, Campbell MT, Shah AY, Alhalabi O, Kamat AM, Adibi M, Dinney CP, Guo CC, Shen Y, Gao J, Sharma P. Updated results from a pilot trial of neoadjuvant durvalumab in combination with tremelimumab for cisplatin-ineligible high-risk urothelial carcinoma. ASCO 2026, 2026.
4. Moussa MJ, Crupi E, Thomas Z, Shah AY, Gao J, Goswami S, Msaouel P, Jiang CY, Johns A, Glover M, Tannir NM, Siefker-Radtke AO, Campbell MT, Alhalabi AO. Circulating tumor DNA (ctDNA) dynamics as early biomarkers of response to enfortumab vedotin plus pembrolizumab (EVP) in advanced urothelial carcinoma (aUC). ASCO 2026, 2026.
5. Cai EY, Zhang L, Reyes KR, Thomas Z, Jiang CY, Oh E, Jindal T, Zhong JY, Casas SJ, Fahey C, Gupta S, Shah S, Basu A, Grivas P, Tripathi A, Brown JR, Alhalabi O, Tsung I, Campbell MT, S Koshkin AV. Clinical and genomic predictors of outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin and pembrolizumab (EVP): UNITE study analysis. ASCO 2026, 2026.
6. Attia AM, Diaz Tejada LA, PrÃncipe Osorio FA, Flores Hernandez IA, Alhalabi O, Campbell MT, Jiang CY, Thomas Z, Altan M, Gao J, Sheshadri AA. Incidence and risk factors for pneumonitis in patients with urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab: A retrospective cohort study. ASCO 2026, 2026.
7. Crupi E, Gao J, Corn PG, Pagliaro LC, Guo CC, Czerniak B, Moussa MJ, Thomas Z, Jiang CY, Alhalabi O, Campbell MT, O Siefker-Radtke AA. Phase II study of frontline gemcitabine, 5-fluorouracil/leucovorin, and cisplatin (GemFLP) in advanced urachal and non-urachal urinary tract adenocarcinoma. ASCO 2026, 2026.
8. Zhong JY, Jang A, Jindal T, Jiang CY, Thomas Z, Oh E, Nguyen CB, Bakaloudi D, Jaime-Casas S, Tripathi A, Grivas P, Tsung I, Campbell MT, Alhalabi O, Reimers MA, Khaki AR, Chen Z, Fu P, Koshkin VS, Robert Brown AJ. Effect of on-treatment dose adjustments on the efficacy of enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC): A UNITE analysis. ASCO 2026, 2026.
9. Jiang CY, Hwang H, Thomas Z, Jindal T, Cai EY, Jang A, Oh E, Bakaloudi DR, Tripathi A, Shah S, Shah S, Gupta S, Grivas P, Tsung I, Brown JR, Koshkin VS, Campbell MT, Alhalabi O. Outcomes with subsequent therapies post-enfortumab vedotin/pembrolizumab (EVP) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study. ASCO 2026, 2026.
10. Seyedin SN, Semaan M, Macaraeg A, Raad A, Reyes KR, Dufault S, Parikh M, Stefanoudakis D, Drakaki A, Hashemi-Sadraei N, Thomas Z, Jiang CY, Campbell MT, Alhalabi O, Friedlander TW, Koshkin VS, Mar N. Concurrent use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) in patients (pts) with advanced urothelial carcinoma (UC) receiving enfortumab vedotin (EV) plus pembrolizumab (P) therapy. ASCO 2026, 2026.
11. Jindal T, Cai EY, Reyes KR, Jiang CY, Thomas Z, Jang A, Zhong JY, Alhalabi O, Campbell MT, Koshkin VS, Brown JR. Predictive value of early circulating tumor DNA (ctDNA) response in advanced urothelial carcinoma (aUC) treated with enfortumab vedotin plus pembrolizumab (EVP). ASCO 2026, 2026. e-Pub 2026.
12. Nizam A, Jindal T, Cai E, Jiang CY, Thomas Z, Oh E, Nguyen CB, Jang A, Zhong J, Reyes K, Jaime-Casas S, Bakaloudi DR, Khaki AR, Govindarajan A, Gupta S, Shah SA, Milowsky MI, Grivas P, Tripathi A, Brown JR, Tsung I, Campbell MT, Alhalabi O, Koshkin VS. A0861 Factors associated with inferior outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with first-line enfortumab vedotin plus pembrolizumab (1L EV+P): results from UNITE. European Urology 2026, 2026.
13. Thomas Z, Johns A, Glover M, Crupi E, Lin JK, Ward JF, Karam JA, Hofstetter WL, Desai MD, Choi S, Shah AY, Nieto Y, Moussa MJ, Jiang CY, Alhalabi O, Campbell MT. Divergent biology and outcomes of somatic transformations (SM) in germ cell tumors (GCT). ASCO 2026, 2026.
14. Cai EY, Zhang L, Reyes KR, Thomas Z, Jiang CY, Oh E, Jindal T, Zhong JY, Jaime-Casas S, Fahey C, Gupta S, Shah S, Basu A, Grivas P, Tripathi A, Brown JR, Alhalabi O, Tsung I, Campbell MT, Koshkin VS. Enfortumab vedotin and pembrolizumab (EVP) outcomes in patients (pts) with advanced urothelial carcinoma (aUC) and FGFR3 alterations: UNITE study analysis. ASCO 2026, 2026.
15. Jacques Carriere PP, Alhalabi O, Kamat AM, Gao J, Goswami S, Campbell MT, Shah AY, Jiang CY, Glover M, Bree K, Lee BH, Navai N, Lozano C, Rooney MK, Mohamad O, Hoffman KE, Choi S, Tran PT, Hassanzadeh C. CONSOLIDATE: A phase I/II study of radiotherapy combined with enfortumab vedotin (EV) for locally advanced bladder cancer with paired translational ctDNA and utDNA. ASCO 2026, 2026.
16. Jindal T, Jiang CY, Cai EY, Zhong JY, Oh E, Casas S, Bakaloudi D, Emamekhoo H, Zakharia Y, Nizam A, Milowsky MI, Shah S, Basu A, Grivas P, Tripathi A, Tsung I, Brown JR, Alhalabi O, Koshkin VS. Impact of prior immune checkpoint inhibitor (ICI) and interval from ICI exposure on outcomes with enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC). ASCO 2026, 2026.
17. Thomas Z, Jiang CY, Speck P, Moussa MJ, Crupi E, Gao J, Desai MD, Shah AY, Goswami S, Siefker-Radtke AO, Johns A, Glover M, Logothetis C, Msaouel P, Aaroe A, Patel AB, Campbell MT, Alhalabi O. Correlation of adverse events (AEs) and clinical outcomes in first-line enfortumab vedotin-pembrolizumab (EVP) treatment for locally advanced or metastatic urothelial cancer (La/mUC). ASCO 2026, 2026.
18. Zhong JY, Jang A, Jindal T, Jiang CY, Thomas Z, Oh E, Nguyen CB, Bakaloudi D, Casas S, Tripathi A, Grivas P, Tsung I, Campbell MT, Alhalabi O, Reimers MA, Khaki AR, Chen Z, Fu P, Koshkin VS, Brown JR. Effect of upfront dose reductions on efficacy of enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC): A UNITE analysis. ASCO 2026, 2026.
19. Reyes KR, Zhang L, Cai EY, Thomas Z, Jiang CY, Oh E, Jindal T, Zhong JY, Jaime-Casas S, Milowsky MI, Nizam A, Shah S, Basu A, Grivas P, Tripathi A, Brown JR, Alhalabi O, Tsung I, Campbell MT, Koshkin VS. Impact of HER2 expression and ERBB2 alterations on clinical outcomes in patients treated with enfortumab vedotin and pembrolizumab (EVP): UNITE study analysis. ASCO 2026, 2026.
20. Moussa MJ, Jiang CY, Varughese, Rawther-Karedath A, Gajagowni S He H. 1064 Clinical and prognostic characterization of high-grade neurologic immune-related adverse events in patients with urinary cancers. Journal for ImmunoTherapy of Cancer 13(2), 2025. e-Pub 2025.
21. Jiang CY, Hwang H, Jindal T, Oh E, Jang A, Milowsky M, Shah S, Zakharia Y, Basu A, Hoimes CJ, Emamekhoo H, Gupta S, Bellmunt J, Tripathi A, Grivas P, Brown J, Tsung I, Koshkin VS, Alhalabi O, Campbell MT. 3094P Validation of prognostic scores 3094P Validation of prognostic scores for advanced urothelial cancer (aUC) for enfortumab vedotin/pembrolizumab (EVP): Analysis of the UNITE studyfor advanced urothelial cancer (aUC) for enfortumab vedotin/pembrolizumab (EVP): Analysis of the UNITE study. ESMO, 2025.
22. Black S, Yu K, Moussa MJ, Jiang CY, Msaouel P, Meric-Bernstam F, Campbell MT, Wang L, Zhao J, Guo CC, Gao J, Alhalabi O. Integrative clinico-genomic evaluation of the human epidermal growth factor receptor 2 (HER2) in urothelial cancer (UC). ASCO 2025, 2025.
23. Jiang CY, Zhang Y, Yu K, Mei Y, Qiao W, Moussa MJ, Chen J, Wang R, Zhao J, Shah AY, Goswami S, Guo CC, Siefker-Radtke AO, Campbell MT, Wang L, Alhalabi O, Gao AJ. Targeting the TGFβ signaling pathway to mitigate tumor metastasis in 9p21-loss urothelial bladder cancer. ASCO 2025, 2025.
24. Chu Y, Chen J, Jiang CY, Mei Y, Zhang Y, Siefker-Radtke A, Gao J. FGFR3 inhibition is a highly effective therapy in MTAP-deficient, FGFR3 altered urothelial carcinoma. American Association for Cancer Research, 2025.
25. Jindal T, Jiang CY, Alhalabi O, Sidhom F, Jang A, Bakaloudi DR, Narula I, Jaime-Casas S, Glover M, Nizam A, Gupta S, Bilen MA, Shah S, Tripathi A, Grivas P, Brown JR, Basu A, Campbell MT, Alva AS, S Koshkin AV. Outcomes of enfortumab vedotin and pembrolizumab for patients previously treated with immune checkpoint inhibitors in the UNITE study. ASCO GU 2025, 2025.
26. Nizam A, Zhang L, Jiang CY, Nguyen CB, Bakaloudi DR, Bilen MA, Barata PM, Zakharia Y, Milowsky MI, Kilari D, Hoimes CJ, Khaki AR, Emamekhoo H, Gupta S, Grivas P, Bellmunt J, Alva AS, Campbell MT, Alhalabi O, Koshkin VS. 1972P Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE. ESMO Congress 2024 35:S1142, 2024. e-Pub 2024.
27. Nizam A, Zhang L, Jiang CY, Nguyen CB, Bakaloudi DR, Bilen MA, Barata PM, Zakharia Y, Milowsky MI, Kilari D, Hoimes CJ, Khaki AR, Emamekhoo H, Gupta S, Grivas P, Bellmunt J, Alva AS, Campbell MT, Alhalabi O, Koshkin VS. Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE. ESMO 2024, 2024.
28. Jang A, Jindal T, Jiang CY, Nguyen CB, Nizam A, Alva AS, Grivas P, Bellmunt J, Hoimes CJ, Bilen MA, Emamekhoo H, Milowsky MI, Khaki AR, Gupta S, Campbell MT, Alhalabi O, Chen Z, Fu P, Koshkin VS, Brown JR. 1989P Efficacy of enfortumab vedotin (EV) in patients (pts) with (w) advanced urothelial carcinoma (aUC) who have baseline neuropathy (N) and/or diabetes mellitus (DM): A UNITE study analysis. ESMO Congress 2024 35:S1150-S1151, 2024. e-Pub 2024.
29. Jang A, Jindal T, Jiang CY, Nguyen CB, Nizam A, Alva AS, Grivas P, Bellmunt J, Hoimes CJ, Bilen MA, Emamekhoo H, Milowsky MI, Khaki AR, Gupta S, Campbell MT, Alhalabi O, Chen Z, Fu P, Koshkin VS, Brown JR. Efficacy of enfortumab vedotin (EV) in patients (pts) with (w) advanced urothelial carcinoma (aUC) who have baseline neuropathy (N) and/or diabetes mellitus (DM): A UNITE study analysis. ESMO 2024, 2024. e-Pub 2024.
30. Jindal T, Jiang CY, Alhalabi O, Tsung I, Jang A, Bakaloudi DR, Sidhom F, Taylor AK, Hoimes CJ, Bellmunt J, Bilen MA, Gupta S, Milowsky MI, Shah S, Basu A, Grivas P, Brown JR, Campbell MT, Alva AS, Koshkin VS. 1988P Enfortumab vedotin (EV) + pembrolizumab (P) outcomes outside clinical trials and biomarkers of benefit in patients (pts) with advanced urothelial carcinoma: Analysis of the UNITE study. ESMO Congress 35:S1149-S1150, 2024. e-Pub 2024.
31. Jiang CY, Jindal T, Epstein IB, Nguyen CB, Nizam A, Bakaloudi DR, Taylor AK, Milowsky MI, Shah S, Hoimes CJ, Bilen MA, Zakharia Y, Emamekhoo H, Grivas P, Gupta S, Bellmunt J, Alva AS, Koshkin VS, Alhalabi O, T Campbell AM. Efficacy of erdafitinib in FGFR2/3-altered metastatic urothelial cancer including patients with CDK2NA/B or MTAP loss: Analysis of UNITE study. ASCO 2024, 2024. e-Pub 2024.
32. Jiang C, Jiang C, Alhalabi O, Nguyen CB, Nizam A, Bas A, Zakharia Y, Bilen MA, Brown J, Milowsky M, Kilari D, Emamekhoo H, Hoimes CJ, Shah S, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva A, Koshkin VS. Factors associated with primary progression in patients with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV): Analysis of the UNITE study. ESMO Targeted Anticancer Therapies Congress 2024, 2024.
33. Jindal T, Jiang C, Alhalabi O, Nguyen CB, Nizam A, Basu A, Zakharia Y, Bilen MA, Brown J, Milowsky M, Kilari D, Emamekhoo H, Hoimes CJ, Shah S, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva A, Koshkin VS. 8P Factors associated with primary progression in patients with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV): Analysis of the UNITE study. ESMO TAT 2024 9, 2024. e-Pub 2024.
34. Jindal T, Jiang CY, Alhalabi O, Nguyen CB, Nizam A, Basu A, Asim M, Bilen, Zakharia Y, Milowsky MI, Brown JR, Kilari D, Emamekhoo H, Christopher J, Hoimes, Khaki AR, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS. Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study. GU ASCO 2024, 2024.
35. Nizam A, Jindal T, Jiang CY, Alhalabi O, Davidsohn MP, Bakaloudi DR, Talukder R, Nguyen CB, Oh E, Taylor AK, Bilen MA, Basu A, Kilari D, Emamekhoo H, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS. Outcomes with sacituzumab govitecan (SG) in patients (pts) with advanced urothelial carcinoma (aUC) and variant histologies (VH): Analysis of the UNITE study. GU ASCO 2024, 2024.
36. Jiang CY, Hwang H, Jindal T, Qiao W, Epstein I, Nguyen CB, Gupta S, Shah S, Bilen MA, Milowsky MI, Hoimes CJ, Kilari D, Zakharia Y, Emamekhoo H, Grivas P, Bellmunt J, Alva AS, Koshkin VS, Campbell MT, Alhalabi AO. Sequencing of erdafitinib (erda) and enfortumab vedotin (EV) in patients (pts) with fibroblast growth factor receptor (FGFR2/3) altered (alt) advanced urothelial cancer (aUC): Analysis of UNITE database. GU ASCO 2024, 2024.
37. Nizam A, Jindal T, Jiang CY, Alhalabi O, Bakaloudi DR, Talukder R, Davidsohn MP, Nguyen CB, Oh E, Taylor AK, Lemke E, Kilari D, Hoimes CJ, Emamekhoo H, Gupta S, Bellmunt J, Grivas P, Campbell MT, Alva AS, Koshkin VS. Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study. GU ASCO 2024, 2024.
38. Jiang C, Ravishankar S, Zhao L, Green M, Towlerton A, Scott A, Raghavan M, Cusick M, Warren EH, Ramnath N. Role of HLA-DRB4 as a biomarker for endocrine toxicity and survival outcomes after immunotherapy in metastatic non-small cell lung cancer. ASCO 2023, 2023.
39. Jiang CY, Navai N, Tidwell RS, Jindal S, Macaluso M, Siefker-Radtke AO, Goswami S, Campbell MT, Shah AY, Alhalabi O, Kamat AM, Adibi M, Dinney CP, Guo CC, Shen Y, Gao J, Sharma AP. Updated results from a pilot trial of neoadjuvant durvalumb in combination with tremelimuab for cisplatin-ineligible high-risk urothelial carcinoma. ASCO 2026, 2023.
40. Jindal T, Zhang L, Jiang C, Kilari D, Alhalabi O, Nizam A, Basu A, Mehmet A, Bilen, Zakharia Y, Milowsky MI, Shah S, Hoimes CJ, Davis NB, Gupta S, Emamekhoo H, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS. Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study. ASCO 2023, 2023.
41. Jindal T, Jiang C, Alhalabi O, Bakaloudi DR, Talukder R, Davidsohn M, Nizam A, Taylor AK, Nguyen CB, Kilari D, Pywell C, Davis NB, Emamekhoo H, Sonpavde GP, Gupta S, Bellmunt J, Grivas P, Campbell MT, Alva AS, Koshkin VS. Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study. ASCO 2023, 2023.
42. Jiang C, Alhalabi O, Haro-Silerio J, Qiao W, Shah AY, Siefker-Radtke AO, Gao J, Goswami S, Alva AS, Koshkin VS, Guo C, Campbell MT. Clinical efficacy analysis of patients (pts) with HER-2 expressing metastatic urothelial carcinoma (mUC) treated with enfortumab vedotin (EV). ASCO 2023, 2023.
43. Jiang C, Zhao L, Schuetze S, Chugh R. Giant cell tumor of bone: Effect of longer dosing intervals of denosumab on tumor control and bone related complications. University of Michigan Internal Medicine Research Symposium, 2022.
44. Jiang C, Zhao L, Schuetze S, Chugh R. Giant cell tumor of bone: Effect of longer dosing intervals of denosumab on tumor control and bone related complications. American Society of Clinical Oncology Annual meeting, 2022. e-Pub 2021.
45. Jiang C, Strohbehn GW, Dedinsky R, Raupp S, Pannecouk B, Yentz SE, Ramnath N. Assessment of patient satisfaction, financial, and environmental impacts of teleoncology. 2021 ASCO Quality Care Symposium 39(28_suppl):278-278, 2021. e-Pub 2021.
46. Jiang CY, Strohbehn GW, Dedinsky RM, Raupp SM, Pannecouk BM, Yentz SE, Ramnath N. Teleoncology for Veterans: High Patient Satisfaction Coupled With Positive Financial and Environmental Impacts. ASCO Quality Care Symposium, 2021.
47. Jiang CY, Madhani N, Shah BK, Dall L. The Sensitivity of Procalcitonin Levels in Patients with Viridans Streptococci Endocarditis. 4th Annual Vijay Babu Raydu Quality and Patient Safety Day. e-Pub 2017.
48. Jiang C. The Role of Heavy Metal Resistant Bacteria (Bacillus megaterium, Bacillus licheniformis) on the Bioaccumulation of Lead in Helianthus annuus. Missouri Junior Academy of Science.
49. Jiang C. The Role of Heavy Metal Resistant Bacteria (Bacillus megaterium, Bacillus licheniformis) on the Bioaccumulation of Lead in Helianthus annuus. Intel International Science and Engineering Fair (ISEF).
50. Jiang CY, Madhani N, Shah BK, Dall L. The Utility of Procalcitonin Levels in the Detection of Viridans Streptococci Endocarditis. UMKC Health Sciences Student Research Summit.
51. Jiang CY, Madhani N, Shah BK, Dall L. The Utility of Procalcitonin Levels in the Detection of Viridans Streptococci Endocarditis. 5th Annual Vijay Babu Raydu Quality and Patient Safety Day.
52. Jiang CY, Madhani N, Shah BK, Dall L. The Utility of Procalcitonin Levels in the Detection of Viridans Streptococci Endocarditis. Missouri American College of Physicians Scientific Meeting.
53. Jiang CY, Uttal SE, Aggarwal V. A Catastrophic Event [clinical vignette abstract]. American College of Physicians Michigan Chapter Virtual Scientific Meeting.

Letters to the Editor

1. Jindal T, Jiang CY, Alhalabi O, Nguyen CB, Oh E, Tsung I, Bakaloudi DR, Talukder R, Davidsohn M, Freeman D, Epstein IY, Ding CC, Nizam A, Glover MJ, Khaki AR, Taylor AK, Lemke E, Jang A, Evans ST, Shin D, Pywell C, Basu A, Bilen MA, Zakharia Y, Barata P, Milowsky MI, Brown J, Kilari D, Emamekhoo H, Hoimes CJ, Shah S, Davis NB, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS. Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study. Eur Urol 90: 85-87, 2025.